Kala Pharmaceuticals (KALA) Misses Q3 EPS by 126c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($3.41), $1.26 worse than the analyst estimate of ($2.15).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• Schwab's May activity shows margin loans nearly double